| Apixaban. After hip or knee replacement: LMWH remains the standard treatment. | |
| | |
MedLine Citation:
|
PMID: 23016247 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The standard anticoagulant for prevention of venous thromboembolism in patients undergoing hip or knee replacement surgery is a low-molecular-weight heparin (LMWH) such as subcutaneous enoxaparin. Apixaban is the second oral factor Xa inhibitor, after rivaroxaban, to be approved in the European Union for use in these two situations. Three double-blind randomised trials versus enoxaparin in a total of nearly 12 000 patients failed to show that apixaban was more effective in terms of relevant endpoints: mortality, and the incidence of pulmonary embolism and symptomatic deep vein thrombosis. The incidence of bleeding did not differ between the apixaban and enoxaparin groups under the conditions of these trials. Apixaban is mainly metabolised by cytochrome P450 isoenzymes CYP 3A4 and 3A5 and also binds to P-glycoprotein, resulting in a high potential for pharmacokinetic interactions. Renal failure is a risk factor for overdose. Pharmacodynamic interactions are also likely. There is no known antidote for apixaban. In practice, LMWH remains the standard treatment. |
| | |
Authors:
|
- |
Related Documents
:
|
23371327 - Weekly teriparatide injections successfully treated advanced bisphosphonate-related ost... 18807057 - Long-term outcomes after tympanoplasty with and without mastoidectomy for perforated ch... 23475737 - Long-term results of primary stenting for subclavian artery disease. 23403957 - Entecavir and lamivudine therapy for severe acute chronic hepatitis b. 7803737 - Respiratory function after cardiopulmonary bypass: a comparison of bubble and membrane ... 18206917 - Predictors of treatment failure 24 months after surgery for stress urinary incontinence. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Prescrire international Volume: 21 ISSN: 1167-7422 ISO Abbreviation: Prescrire Int Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-09-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9439295 Medline TA: Prescrire Int Country: France |
Other Details:
|
Languages: eng Pagination: 201-2, 204 Citation Subset: T |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of case management in an era of healthcare reform--Part 3.
Next Document: Denosumab and bone metastases. No better than a bisphosphonate.